Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 9/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 9/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | GRN | P28799 | 1/20 | 0.33 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4579151 | 0.80 | MAPT (0.47) | SMN1; SMN2HTT | |
| SCHEMBL4580162 | 0.77 | ALDH1A1 (0.37) | CTSLSMN1; SMN2HTT | |
| SCHEMBL4609315 | 0.76 | TAS1R3 (0.38) | TAS1R3TAS1R1HTT | |
| SCHEMBL4580348 | 0.76 | ABCB1 (0.48) | HTTADRB2ADRB1ADRB3ABCB1 | |
| SCHEMBL18020906 | 0.73 | POLB (0.47) | TAS1R3TAS1R1SMN1; SMN2HTT | |
| SCHEMBL4581623 | 0.73 | KMT2A (0.54) | SMN1; SMN2HTT | |
| SCHEMBL14947134 | 0.73 | TAS1R3 (0.52) | TAS1R3TAS1R1HTTADRB2ADRB1 | |
| SCHEMBL15358753 | 0.73 | TAS1R3 (0.38) | TAS1R3TAS1R1HTT | |
| SCHEMBL20758873 | 0.72 | GRN (0.35) | TAS1R3TAS1R1ADRB2ADRB1ADRB3 | |
| SCHEMBL19312017 | 0.71 | TAS1R3 (0.35) | TAS1R3TAS1R1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351389-B2 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INTERNATIONAL B.V. (NL) | 2008-04-01 | — | — | US | disclosed |
| US-20050090689-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INTERNATIONAL B.V. (NL) | 2005-04-28 | — | — | US | disclosed |
| US-6875864-B2 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INTERNATIONAL B.V. (NL) | 2005-04-05 | — | — | US | disclosed |
| US-20030171561-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO SUISSE SA (CH) | 2003-09-11 | — | — | US | disclosed |
| EP-0543482-B1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INT BV (NL) | 2002-02-06 | — | — | EP | disclosed |
| EP-0543482-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INTERNATIONAL B.V. (NL) | 1993-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171561-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | ARGLU1, PRMT1, AADAC | TAS1R3 203/4885TAS1R1 201/4885CTSL 2578/4885 |
| US-20050090689-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | AADAC, ANXA3, AAAS | TAS1R3 137/4885TAS1R1 488/4885CTSL 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.